Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01409
|
|||||
| Drug Name |
Vildagliptin
|
|||||
| Synonyms |
Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11:5A11] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H25N3O2
|
|||||
| Canonical SMILES |
C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
|
|||||
| InChI |
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
|
|||||
| InChIKey |
SYOKIDBDQMKNDQ-XWTIBIIYSA-N
|
|||||
| CAS Number |
CAS 274901-16-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 303.4 | Topological Polar Surface Area | 76.4 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
12015446
,14849686
,14898545
,17194948
,43529907
,46512217
,50459774
,51091422
,57371966
,99443227
,103381660
,104178744
,114788130
,118314324
,121147405
,124772155
,126651432
,129307316
,134358368
,135683855
,136375110
,137004291
,139563570
,152037539
,152159633
,160967824
,172085080
,172914664
,174477837
,175266579
,175426398
,178102929
,186021611
,196105655
,210275077
,210280715
,224646668
,226406746
,249810559
,251883214
,252032033
,252160316
,252216578
,252308983
|
|||||
| ChEBI ID |
CHEBI:135285
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (I6B4B2U96P) | |||||
| 2 | Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.